Literature DB >> 23130564

American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer.

Robert C Smallridge1, Kenneth B Ain, Sylvia L Asa, Keith C Bible, James D Brierley, Kenneth D Burman, Electron Kebebew, Nancy Y Lee, Yuri E Nikiforov, M Sara Rosenthal, Manisha H Shah, Ashok R Shaha, R Michael Tuttle.   

Abstract

BACKGROUND: Anaplastic thyroid cancer (ATC) is a rare but highly lethal form of thyroid cancer. Rapid evaluation and establishment of treatment goals are imperative for optimum patient management and require a multidisciplinary team approach. Here we present guidelines for the management of ATC. The development of these guidelines was supported by the American Thyroid Association (ATA), which requested the authors, members the ATA Taskforce for ATC, to independently develop guidelines for ATC.
METHODS: Relevant literature was reviewed, including serial PubMed searches supplemented with additional articles. The quality and strength of recommendations were adapted from the Clinical Guidelines Committee of the American College of Physicians, which in turn was developed by the Grading of Recommendations Assessment, Development and Evaluation workshop.
RESULTS: The guidelines include the diagnosis, initial evaluation, establishment of treatment goals, approaches to locoregional disease (surgery, radiotherapy, systemic therapy, supportive care during active therapy), approaches to advanced/metastatic disease, palliative care options, surveillance and long-term monitoring, and ethical issues including end of life. The guidelines include 65 recommendations.
CONCLUSIONS: These are the first comprehensive guidelines for ATC and provide recommendations for management of this extremely aggressive malignancy. Patients with stage IVA/IVB resectable disease have the best prognosis, particularly if a multimodal approach (surgery, radiation, systemic therapy) is used, and some stage IVB unresectable patients may respond to aggressive therapy. Patients with stage IVC disease should be considered for a clinical trial or hospice/palliative care, depending upon their preference.

Entities:  

Mesh:

Year:  2012        PMID: 23130564     DOI: 10.1089/thy.2012.0302

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  235 in total

1.  Establishment and characterization of novel human primary and metastatic anaplastic thyroid cancer cell lines and their genomic evolution over a year as a primagraft.

Authors:  Manoj Garg; Ryoko Okamoto; Yasunobu Nagata; Deepika Kanojia; Subhashree Venkatesan; Anand M T; Glenn D Braunstein; Jonathan W Said; Ngan B Doan; Quoc Ho; Tadayuki Akagi; Sigal Gery; Li-Zhen Liu; Kar Tong Tan; Wee Joo Chng; Henry Yang; Seishi Ogawa; H Phillip Koeffler
Journal:  J Clin Endocrinol Metab       Date:  2014-11-03       Impact factor: 5.958

2.  Multimodality Treatment Improves Locoregional Control, Progression-Free and Overall Survival in Patients with Anaplastic Thyroid Cancer: A Retrospective Cohort Study Comparing Oncological Outcomes and Morbidity between Multimodality Treatment and Limited Treatment.

Authors:  Pascal K C Jonker; John Turchini; Schelto Kruijff; Jia Feng Lin; Anthony J Gill; Thomas Eade; Ahmad Ahniss; Roderick Clifton-Bligh; Diana Learoyd; Bruce Robinson; Venessa Tsang; Anthony Glover; Stanley Sidhu; Mark Sywak
Journal:  Ann Surg Oncol       Date:  2021-05-25       Impact factor: 5.344

3.  Anaplastic Thyroid Carcinoma, Version 2.2015.

Authors:  Robert I Haddad; William M Lydiatt; Douglas W Ball; Naifa Lamki Busaidy; David Byrd; Glenda Callender; Paxton Dickson; Quan-Yang Duh; Hormoz Ehya; Megan Haymart; Carl Hoh; Jason P Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M Lamonica; Judith C McCaffrey; Jeffrey F Moley; Lee Parks; Christopher D Raeburn; John A Ridge; Matthew D Ringel; Randall P Scheri; Jatin P Shah; Robert C Smallridge; Cord Sturgeon; Thomas N Wang; Lori J Wirth; Karin G Hoffmann; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2015-09       Impact factor: 11.908

4.  Anaplastic thyroid carcinomas incidentally found on postoperative pathological examination.

Authors:  Akira Yoshida; Kiminori Sugino; Iwao Sugitani; Akira Miyauchi
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

5.  Bioluminescent human thyrospheres allow noninvasive detection of anaplastic thyroid cancer growth and metastases in vivo.

Authors:  Ashley N Reeb; Wen Li; Reigh-Yi Lin
Journal:  Thyroid       Date:  2014-05-20       Impact factor: 6.568

6.  Overall Survival of Patients with Aggressive Thyroid Cancer on Fine-Needle Aspiration Biopsy Examination. A Tertiary Romanian Center Experience.

Authors:  Iustina Cosmina Mogos; Dan Alexandru Niculescu; Dumitru Ioachim; Radu Iorgulescu; Catalina Poiana
Journal:  Maedica (Buchar)       Date:  2015-09

7.  Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.

Authors:  Soeren Latteyer; Vera Tiedje; Katharina König; Saskia Ting; Lukas C Heukamp; Lydia Meder; Kurt Werner Schmid; Dagmar Führer; Lars Christian Moeller
Journal:  Endocrine       Date:  2016-10-01       Impact factor: 3.633

8.  Anaplastic thyroid carcinoma: changing trends of treatment strategies and associated overall survival.

Authors:  Sabine Wächter; C Vorländer; J Schabram; I Mintziras; I Fülber; J Manoharan; K Holzer; D K Bartsch; E Maurer
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-02-14       Impact factor: 2.503

9.  miR30a inhibits LOX expression and anaplastic thyroid cancer progression.

Authors:  Myriem Boufraqech; Naris Nilubol; Lisa Zhang; Sudheer Kumar Gara; Samira M Sadowski; Amit Mehta; Mei He; Sean Davis; Jennifer Dreiling; John A Copland; Robert C Smallridge; Martha M Quezado; Electron Kebebew
Journal:  Cancer Res       Date:  2014-12-08       Impact factor: 12.701

10.  Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.

Authors:  Teresa Di Desidero; Paola Orlandi; Daniela Gentile; Marta Banchi; Greta Alì; Claudia Kusmic; Paolo Armanetti; Ginelle J Cayme; Luca Menichetti; Gabriella Fontanini; Giulio Francia; Guido Bocci
Journal:  Pharmacol Res       Date:  2020-05-24       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.